FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial
Journal article published in 2019 by
James M. Cleary 
,
Nora K. Horick,
Nadine Jackson McCleary ,
Thomas A. Abrams,
Matthew B. Yurgelun,
Christopher G. Azzoli,
Douglas A. Rubinson,
Gabriel A. Brooks ,
Jennifer A. Chan,
Lawrence S. Blaszkowsky,
Jeffrey W. Clark,
Lipika Goyal,
Jeffrey A. Meyerhardt,
Kimmie Ng,
Deborah Schrag
and other authors.
,
Nora K. Horick,
Nadine Jackson McCleary ,
Thomas A. Abrams,
Matthew B. Yurgelun,
Christopher G. Azzoli,
Douglas A. Rubinson,
Gabriel A. Brooks ,
Jennifer A. Chan,
Lawrence S. Blaszkowsky,
Jeffrey W. Clark,
Lipika Goyal,
Jeffrey A. Meyerhardt,
Kimmie Ng,
Deborah Schrag
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 